50 results about "Antibody Interactions" patented technology

The invention relates to the diagnosis, monitoring, prognosis, and / or prediction of cancer utilizing the detection or measurement of glycan-protein interactions, particularly glycan-antibody interactions. The invention relates to carbohydrate-containing molecules that are utilized in bioanalytical systems, methods and kits for detecting neoplasia and methods related thereto and based thereon. In an exemplary embodiment glycans or glycopolymers are carried in an array, on beads or in a microfluidic system for diagnostic screening for risk of neoplasia, the existence of neoplasia in a patient, or for treatment monitoring. In such an embodiment, the bioanalytic system identifies binding interactions between molecules in a patient test sample (e.g., glycan compositions) and the glycans or glycopolymers. The glycan-binding compositions may be used to generate an immune response against cancer cell epitopes. Alternatively, antibody therapeutics can be developed that are useful for binding to glycan compositions on a cell surface.

The invention discloses an anti-EGFR human source antibody MIL27 based on computer aided design and application thereof. The antibody can be used for obviously inhibiting and killing human cancer cell expressing EGFR. The invention is based on the interaction structure characteristic of EGFR protein extracellular region and functional antibody, computer virtual screening and design are adopted to obtain the anti-EGFR functional human source antibody MIL27, PCR method is applied to complete synthesis of antibody gene, eukaryotic expression vector is constructed, and MIL27 antibody capable of specifically identifying EGFR is expressed. The antibody MIL27 can effectively kill EGFR positive tumour cells, including blaster cancer cell and liver cancer cell. The antibody identifies EGFR new epitope, and competitive experiment verifies that the new epitope is different from EGFR epitope identified by Erbitux.

The invention relates to the diagnosis, monitoring, prognosis, and / or prediction of cancer utilizing the detection or measurement of glycan-protein interactions, particularly glycan-antibody interactions. The invention relates to carbohydrate-containing molecules that are utilized in bioanalytical systems, methods and kits for detecting neoplasia and methods related thereto and based thereon. In an exemplary embodiment glycans or glycopolymers are carried in an array, on beads or in a microfluidic system for diagnostic screening for risk of neoplasia, the existence of neoplasia in a patient, or for treatment monitoring. In such an embodiment, the bioanalytic system identifies binding interactions between molecules in a patient test sample (e.g., glycan compositions) and the glycans or glycopolymers. The glycan-binding compositions may be used to generate an immune response against cancer cell epitopes. Alternatively, antibody therapeutics can be developed that are useful for binding to glycan compositions on a cell surface.

The invention relates to the diagnosis, monitoring, prognosis, and / or prediction of cancer utilizing the detection or measurement of glycan-protein interactions, particularly glycan-antibody interactions. The invention relates to carbohydrate-containing molecules that are utilized in bioanalytical systems, methods and kits for detecting neoplasia and methods related thereto and based thereon. In an exemplary embodiment glycans or glycopolymers are carried in an array, on beads or in a microfluidic system for diagnostic screening for risk of neoplasia, the existence of neoplasia in a patient, or for treatment monitoring. In such an embodiment, the bioanalytic system identifies binding interactions between molecules in a patient test sample (e.g., glycan compositions) and the glycans or glycopolymers. The glycan-binding compositions may be used to generate an immune response against cancer cell epitopes. Alternatively, antibody therapeutics can be developed that are useful for binding to glycan compositions on a cell surface.

The invention relates to a fluorescent biosensing method for inhibiting and analyzing and detecting interaction between micromolecules and binding protein based on restrictive incision enzyme FokI, which comprises an interaction between an oligonucleotides DNA chain which is modified by organic micromolecules and a protein, formation conditions for the restrictive incision enzyme FokI dipolymer and selection of inhibition locus, and real-time fluorescence quantitative detecting technology based on a Taqman probe. By utilizing specificity combination of the micromolecules modifying among the oligonucleotides DNA chain and the binding protein thereof or antibodies, the interaction between the micromolecules and the protein and the micromolecules or the binding protein thereof can be detected through a real-time quantitative analysis on enzyme incision Taqman probe fluorescence based on the inhibition effect on the incision of the restrictive incision enzyme FokI by the interaction between the micromolecules and the proteins or the antibodies. The method has the advantages of high sensitivity, simple and convenient operation, and high specificity, and can be used for study on signal transduction and molecular regulation mechanism in biomedicine, safety detection of foods and agricultural products, detection on environmental toxicant, medicine screening and the like.

The present invention relates to a biopolymer detection method based on antigen-antibody interaction, wherein the method shows improved S / N ratio, improved detection sensitivity and reduced detection time. The present invention also relates to the application of these methods on biochips. The present invention also relates to an antibody immobilization method in which antibody molecules are immobilized on an amide group-containing gel, or an amide group-containing gel on an insoluble substance. Use of such gels prevents non-specific adsorption of antibody binding molecules. By embedding these antibody-binding molecules in such a gel, degradation of their antibody-binding activity is prevented. A method for detecting a biopolymer by capturing a target biopolymer to a substrate surface, comprising the following steps: (1) attaching a target biopolymer, together with a probe biopolymer and an antibody or address probe peptide or a peptide bound to them (2) hybridize the target biopolymer to the probe biopolymer; and (3) through the antigen-antibody interaction, through the address probe peptide Or biopolymer or polyclonal antibody molecules to recognize the address linker bound to the substrate. The method of immobilizing antibodies comprises the steps of: (1) applying a gel containing amide groups embedded with antibody binding molecules on a matrix of insoluble substances in two or three dimensions; and (2) attaching the bases of antibody molecules to the antibody binding molecule.

The invention relates to a method for detecting interaction of an antibody and polypeptides by adopting capillary electrophoresis, belonging to the field of bioanalysis. The method comprises the steps of firstly, mixing the antibody with polypeptides of different proportions, then carrying out capillary electrophoresis detection, simultaneously detecting an appearance time and a fluorescence intensity of an antibody polypeptide compound and a fluorescence polypeptide, integrating an electrophoresis peak of the antibody polypeptide compound, converting an integral area into a compound concentration, and calculating a dissociation constant (KD) of the antibody and the polypeptide according to a formula. The method can also be used for detecting a competition process of the interaction of two exogenous polypeptides and the antibody. Experiments prove that the method has the advantages of simpleness in operation, high detection sensitivity, and short required time. The method is a novel high-sensitivity technology for detecting the interaction of the polypeptides and the antibody through improvement of the traditional technology of detecting the interaction of the polypeptides and the antibody and combination with the advantages of high sensitivity and the like of fluorescence detection.

The invention provides a fluorescent biosensing method for analyzing and detecting mutual action of organic micromolecules and combined protein based on a T7 exonuclease inhibition. The method comprises mutual action of an oligonucleotide DNA (Deoxyribonucleic Acid) single chain with the middle part modified by organic micromolecules and protein, selection of a T7 exonuclease inhibition site, and a real-time fluorescent quantitative detection technique based on a Taqman probe. The method provided by the invention can be used for detecting the mutual action of the organic micromolecules and the protein, and the organic micromolecules or conjugated protein thereof through the fluorescent real-time quantitative analysis of the Taqman probe subjected to enzyme digestion based on the inhibition effect of the mutual action of the organic micromolecules and the protein or an antibody to T7 exonuclease by utilizing the specific binding of the organic micromolecules modifying the middle part of the oligonucleotide DNA chain and the conjugated protein or antibody thereof. The method provided by the invention is high in sensitivity, simple and convenient in operation and strong in specificity, and can be used for signal transduction and molecule regulation and control mechanism research in biomedicine, food and farm product security detection, environmental poison detection,drug screening and the like.

The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.

Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.

The invention discloses a computer-assisted design of novel anti-EGFR humanized antibody TGM10 and application thereof. The antibody can be used for inhibiting the growth of human tumor cell for expressing EGFR. The invention obtains the novel anti-EGFR humanized antibody TGM10 by virtual screening and designing of a computer on the basis of the structural characteristic that an EGFR protein cell outer region interacts with the functional antibody. The PCR method is applied to carry out the total synthesis of antibody gene to build into a eukaryon expression carrier, and 9 types of TGM10 antibodies capable of specifically recognizing EGFR can be expressed. The antibody TGM10-1 can effectively kill the positive EGFR tumor cells comprising breast cancer cell lines SKOV3, liver cancer cell lines HepG2 and lung cancer cell lines A549.

The present invention relates to a method for visually detecting antigen-antibody reactions and its application. The method uses enzymes to catalyze substrate reactions to produce reducing products, which reduce divalent copper ions to monovalent copper ions. The click chemical reaction catalyzed by gold nanoparticles and monovalent copper is used to visually analyze the enzyme content; combined with the enzyme-labeled antibody technology, the enzyme-labeled antibody is used in the immunoassay of antigen-antibody interaction, and the enzyme content is analyzed visually The method achieves the purpose of visual analysis of antigen-antibody interaction; the method is used for visual detection of relevant antigen-antibody in clinical samples. The invention can complete the detection of the antigen-antibody reaction only by naked eyes, and has the advantages of high sensitivity, simple operation, low cost, good stability and the like.

This invention describes a quantitative, inexpensive, disposable immunosensor that requires no wash steps and thus generates no liquid waste. Moreover, in preferred embodiments of the sensor no timing steps are required of the user, and the sensor can be readily adapted to antigen-antibody interactions over a wide kinetic range.